IL115505A0 - Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases - Google Patents

Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases

Info

Publication number
IL115505A0
IL115505A0 IL11550595A IL11550595A IL115505A0 IL 115505 A0 IL115505 A0 IL 115505A0 IL 11550595 A IL11550595 A IL 11550595A IL 11550595 A IL11550595 A IL 11550595A IL 115505 A0 IL115505 A0 IL 115505A0
Authority
IL
Israel
Prior art keywords
cyclooxygenase
inhibitors
treatment
neurodegenerative diseases
neurodegenerative
Prior art date
Application number
IL11550595A
Other versions
IL115505A (en
Original Assignee
Merck Sharp & Dohme
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Merck Frosst Canada Inc filed Critical Merck Sharp & Dohme
Publication of IL115505A0 publication Critical patent/IL115505A0/en
Publication of IL115505A publication Critical patent/IL115505A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
IL11550595A 1994-10-12 1995-10-03 Use of inhibitors of cyclooxygenase in the preparation of medicaments for the treatment of neurodegenerative diseases IL115505A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9420616A GB9420616D0 (en) 1994-10-12 1994-10-12 Method, compositions and use

Publications (2)

Publication Number Publication Date
IL115505A0 true IL115505A0 (en) 1996-01-19
IL115505A IL115505A (en) 1999-12-31

Family

ID=10762753

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11550595A IL115505A (en) 1994-10-12 1995-10-03 Use of inhibitors of cyclooxygenase in the preparation of medicaments for the treatment of neurodegenerative diseases

Country Status (6)

Country Link
EP (1) EP0785778A1 (en)
JP (1) JPH10507445A (en)
GB (1) GB9420616D0 (en)
IL (1) IL115505A (en)
WO (1) WO1996011676A1 (en)
ZA (1) ZA958558B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US6515014B2 (en) 1995-06-02 2003-02-04 G. D. Searle & Co. Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US5985930A (en) 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
EP1138324A1 (en) * 1996-11-21 2001-10-04 The Mount Sinai School of Medicine of New York University Treatment of neurodegenerative conditions with nimesulide
ES2185154T3 (en) * 1997-04-03 2003-04-16 Searle & Co METHOD OF USE OF CYCLLOXYGENASA-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF DEMENTIA.
TW200408621A (en) 2002-04-08 2004-06-01 Glaxo Group Ltd Compounds
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3103372A1 (en) * 1981-01-27 1982-09-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen NEW INDANYL DERIVATIVES, THEIR PRODUCTION AND USE
ATE17480T1 (en) * 1982-03-03 1986-02-15 Du Pont ANTI-INFLAMMATORY AND/OR ANALAGIC 2,3-DIARYL-5-HALO THIOPHENE.
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
GB9012936D0 (en) * 1990-06-11 1990-08-01 Fujisawa Pharmaceutical Co Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
DE4219154C2 (en) * 1992-06-11 1995-04-20 Ford Werke Ag Roller or sprag freewheel with additional roller bearings on the side
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
WO1994015932A1 (en) * 1993-01-15 1994-07-21 G.D. Searle & Co. Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
US5409944A (en) * 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
AU6718494A (en) * 1993-05-13 1994-12-12 Merck Frosst Canada Inc. 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
TW416958B (en) * 1993-05-14 2001-01-01 Pfizer Enantioselective oxazaborolidine catalysts
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
CN1143365A (en) * 1994-01-10 1997-02-19 麦克弗罗斯特(加拿大)有限公司 Phenyl-heterocycles as COX-2 inhibitors

Also Published As

Publication number Publication date
GB9420616D0 (en) 1994-11-30
ZA958558B (en) 1997-04-04
EP0785778A1 (en) 1997-07-30
IL115505A (en) 1999-12-31
JPH10507445A (en) 1998-07-21
WO1996011676A1 (en) 1996-04-25

Similar Documents

Publication Publication Date Title
HK1042475A1 (en) Substituted thiazoles for the treatment of inflammation
PT1083889E (en) TETRA-HYDROFOLANTALINE COMPOUNDS AND ITS USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
GB9518115D0 (en) Triazole derivatives and their use as therapeutic agents
IL132318A0 (en) Substituted imidazoles useful in the treatment of inflammatory diseases
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
PL348059A1 (en) Compounds useful in the treatment of inflammatory diseases
HU9602583D0 (en) Gel for treatment of skin diseases and for disinfection of the skin
HK1000697A1 (en) Use of droloxifene for the treatment of cardiovascular diseases
EP0691112A3 (en) Ophthalmic treatment apparatus and its use
AU3959193A (en) Heterocyclic compounds and their use in the treatment of type II-diabetes
AU2466695A (en) The use of famotidine and related compounds in the treatment of movement disorders
IL129144A0 (en) Use of 1-hydroxy-2-pyridones for the treatment of skin diseases
ZA951088B (en) Use of substituted arylcyclobutylalkylamine compounds in the treatment of seizures neurological disorders and neurological damage
GB9816234D0 (en) Compounds for use in the treatment of inflammation
AU9226198A (en) The use of an nadph-oxidase inhibitor in the treatment of reperfusion injury
ZA958558B (en) Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
IL115224A0 (en) Preparations for use in the treatment of osteoporosis
ZA908490B (en) Use of arylalkylamides in the treatment of neurodegenerative diseases
GB2275191B (en) Use of antifungal compounds in the treatment of skin disorders
AU2705495A (en) Use of rooperol and hypoxoside and their derivatives in the treatment of inflammatory
GB9420080D0 (en) The treatment of liquids
GB9424708D0 (en) Use of inflammatory modulators in the treatment of chronic or recalcitrant skin damage
AU3613995A (en) Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
GB2279567B (en) Compositions for the treatment of inflammatory proliferative skin disease and their use
AU3838695A (en) Use of the bio-spectrum in animal embryo-engineering

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees